Achieve Life Sciences, Inc. (ACHV) stock
ACHVNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31Also trades as QUIT
$6.72+0.34 (+5.33%)
Close on Nov 6, 2026Market cap $708.81MP/E –Yield –
Achieve Life Sciences r&d expenses
Research and development expenses are spending on new products and technology.
Achieve Life Sciences's R&D Expenses for the twelve months ending Sep 30, 2025 was $26.42M, up 49.8% year over year. For fiscal 2024 it was $22.82M, up 44.3% from the year before. Over ten years it grew -6.8% a year on average. The highest annual figure on record is $55.32M in fiscal 2013.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $22.82M | +44.3% |
| FY2023 | Dec 31, 2023 | $15.81M | -47.4% |
| FY2022 | Dec 31, 2022 | $30.08M | +25.5% |
| FY2021 | Dec 31, 2021 | $23.97M | +248.2% |
| FY2020 | Dec 31, 2020 | $6.88M | -28.9% |
| FY2019 | Dec 31, 2019 | $9.67M | +64.9% |
| FY2018 | Dec 31, 2018 | $5.87M | +89.2% |
| FY2017 | Dec 31, 2017 | $3.10M | +984.3% |
| FY2016 | Dec 31, 2016 | $286.00K | -98.9% |
| FY2015 | Dec 31, 2015 | $25.11M | -45.7% |
| FY2014 | Dec 31, 2014 | $46.22M | -16.4% |
| FY2013 | Dec 31, 2013 | $55.32M | +38.5% |
| FY2012 | Dec 31, 2012 | $39.95M | +85.3% |
| FY2011 | Dec 31, 2011 | $21.55M | +16.6% |
| FY2010 | Dec 31, 2010 | $18.48M | -8.5% |
| FY2009 | Dec 31, 2009 | $20.21M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | $5.32M | -30.1% |
| Q2 FY2025 | Jun 30, 2025 | $6.71M | +31.2% |
| Q1 FY2025 | Mar 31, 2025 | $7.10M | +153.6% |
| Q4 FY2024 | Dec 31, 2024 | $7.30M | +245.1% |
| Q3 FY2024 | Sep 30, 2024 | $7.61M | +112.5% |
| Q2 FY2024 | Jun 30, 2024 | $5.11M | +11.5% |
| Q1 FY2024 | Mar 31, 2024 | $2.80M | -49.4% |
| Q4 FY2023 | Dec 31, 2023 | $2.11M | -75.5% |
| Q3 FY2023 | Sep 30, 2023 | $3.58M | -63.7% |
| Q2 FY2023 | Jun 30, 2023 | $4.59M | -36.4% |
| Q1 FY2023 | Mar 31, 2023 | $5.53M | +26.1% |
| Q4 FY2022 | Dec 31, 2022 | $8.61M | +91.2% |
| Q3 FY2022 | Sep 30, 2022 | $9.87M | +115.0% |
| Q2 FY2022 | Jun 30, 2022 | $7.21M | -21.9% |
| Q1 FY2022 | Mar 31, 2022 | $4.39M | -22.2% |
| Q4 FY2021 | Dec 31, 2021 | $4.51M | +92.0% |
| Q3 FY2021 | Sep 30, 2021 | $4.59M | +142.8% |
| Q2 FY2021 | Jun 30, 2021 | $9.23M | +736.5% |
| Q1 FY2021 | Mar 31, 2021 | $5.64M | +266.1% |
| Q4 FY2020 | Dec 31, 2020 | $2.35M | +33.1% |
| Q3 FY2020 | Sep 30, 2020 | $1.89M | +3.7% |
| Q2 FY2020 | Jun 30, 2020 | $1.10M | -45.7% |
| Q1 FY2020 | Mar 31, 2020 | $1.54M | -62.0% |
| Q4 FY2019 | Dec 31, 2019 | $1.76M | -15.3% |
| Q3 FY2019 | Sep 30, 2019 | $1.82M | +18.4% |
| Q2 FY2019 | Jun 30, 2019 | $2.03M | +94.4% |
| Q1 FY2019 | Mar 31, 2019 | $4.06M | +237.6% |
| Q4 FY2018 | Dec 31, 2018 | $2.08M | -3.3% |
| Q3 FY2018 | Sep 30, 2018 | $1.54M | +86.8% |
| Q2 FY2018 | Jun 30, 2018 | $1.05M | +1585.5% |
| Q1 FY2018 | Mar 31, 2018 | $1.20M | +1868.9% |
| Q4 FY2017 | Dec 31, 2017 | $2.15M | +2591.3% |
| Q3 FY2017 | Sep 30, 2017 | $825.00K | – |
| Q2 FY2017 | Jun 30, 2017 | $62.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $61.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $80.00K | – |
See a number that looks wrong?